ABBV-744 clinical trial phase 2 data Things To Know Before You Buy
The current work examined the potential of using ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in both equally p53 wild-type (WT) breast tumor cells and in cells missing purposeful p53 possibly alone or in combination with tamoxifen, although the effectiveness of ABBV-74